Pharmaceutical Pricing and Reimbursement Policies in Slovakia:
This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2008
|
| Schriftenreihe: | OECD Health Working Papers
|
| Schlagworte: | |
| Online-Zugang: | UBA01 UBG01 UEI01 UER01 UPA01 UBR01 UBW01 FFW01 FNU01 EUV01 FRO01 FHR01 FHN01 TUM01 FHI01 UBM01 Volltext |
| Zusammenfassung: | This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than it does in any other OECD country, and the share of national income going to pharmaceuticals is exceeded only in Hungary. Although its relatively low national income is a partial explanation for Slovakia's status in this respect, this review finds that Slovakia has scope to reduce its expenditures and the rapid rate of growth in its pharmaceutical spending. Financing of pharmaceutical expenditure in Slovakia rests more heavily on the public sector than is typical in the OECD, with out-of-pocket spending accounting for just a quarter of total expenditure. The effectiveness of international price referencing in limiting Slovak prices for on-patent pharmaceutical products is questionable. For products that have gone off-patent and for those with similar chemical structure, a reference-pricing scheme and competition among generic alternatives results in effective price control, although incentives for generic substitution are weak (for patients) and misaligned (for pharmacists). When deciding whether a drug will be reimbursed through the social insurance scheme, the cost-effectiveness of new pharmaceuticals is not assessed. On the other hand, certain policy goals have been achieved. The accessibility and availability of medicines--including the most innovative products--is good; affordability is supported by relatively low average co-payment levels. While more expensive drugs usually have higher cost-sharing, drugs are not excluded from coverage on affordability grounds |
| Beschreibung: | 1 Online-Ressource (55 Seiten) 21 x 29.7cm |
| DOI: | 10.1787/244264621247 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047934395 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2008 |||| o||u| ||||||eng d | ||
| 024 | 7 | |a 10.1787/244264621247 |2 doi | |
| 035 | |a (ZDB-13-SOC)061280879 | ||
| 035 | |a (OCoLC)1312706848 | ||
| 035 | |a (DE-599)BVBBV047934395 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Kaló, Zoltán |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical Pricing and Reimbursement Policies in Slovakia |c Zoltán Kaló, Elizabeth Docteur and Pierre Moïse |
| 264 | 1 | |a Paris |b OECD Publishing |c 2008 | |
| 300 | |a 1 Online-Ressource (55 Seiten) |c 21 x 29.7cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers | |
| 520 | |a This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than it does in any other OECD country, and the share of national income going to pharmaceuticals is exceeded only in Hungary. Although its relatively low national income is a partial explanation for Slovakia's status in this respect, this review finds that Slovakia has scope to reduce its expenditures and the rapid rate of growth in its pharmaceutical spending. Financing of pharmaceutical expenditure in Slovakia rests more heavily on the public sector than is typical in the OECD, with out-of-pocket spending accounting for just a quarter of total expenditure. The effectiveness of international price referencing in limiting Slovak prices for on-patent pharmaceutical products is questionable. For products that have gone off-patent and for those with similar chemical structure, a reference-pricing scheme and competition among generic alternatives results in effective price control, although incentives for generic substitution are weak (for patients) and misaligned (for pharmacists). When deciding whether a drug will be reimbursed through the social insurance scheme, the cost-effectiveness of new pharmaceuticals is not assessed. On the other hand, certain policy goals have been achieved. The accessibility and availability of medicines--including the most innovative products--is good; affordability is supported by relatively low average co-payment levels. While more expensive drugs usually have higher cost-sharing, drugs are not excluded from coverage on affordability grounds | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 650 | 4 | |a Slovak Republic | |
| 700 | 1 | |a Docteur, Elizabeth |4 ctb | |
| 700 | 1 | |a Moïse, Pierre |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/244264621247 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033315889 | ||
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UBA01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UBG01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UEI01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UER01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UPA01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UBR01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UBW01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FFW01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FNU01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l EUV01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FRO01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FHR01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FHN01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l TUM01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l FHI01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/244264621247 |l UBM01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804183575077060608 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Kaló, Zoltán |
| author2 | Docteur, Elizabeth Moïse, Pierre |
| author2_role | ctb ctb |
| author2_variant | e d ed p m pm |
| author_facet | Kaló, Zoltán Docteur, Elizabeth Moïse, Pierre |
| author_role | aut |
| author_sort | Kaló, Zoltán |
| author_variant | z k zk |
| building | Verbundindex |
| bvnumber | BV047934395 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)061280879 (OCoLC)1312706848 (DE-599)BVBBV047934395 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/244264621247 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04528nmm a2200553zc 4500</leader><controlfield tag="001">BV047934395</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2008 |||| o||u| ||||||eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/244264621247</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)061280879</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312706848</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047934395</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kaló, Zoltán</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical Pricing and Reimbursement Policies in Slovakia</subfield><subfield code="c">Zoltán Kaló, Elizabeth Docteur and Pierre Moïse</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (55 Seiten)</subfield><subfield code="c">21 x 29.7cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than it does in any other OECD country, and the share of national income going to pharmaceuticals is exceeded only in Hungary. Although its relatively low national income is a partial explanation for Slovakia's status in this respect, this review finds that Slovakia has scope to reduce its expenditures and the rapid rate of growth in its pharmaceutical spending. Financing of pharmaceutical expenditure in Slovakia rests more heavily on the public sector than is typical in the OECD, with out-of-pocket spending accounting for just a quarter of total expenditure. The effectiveness of international price referencing in limiting Slovak prices for on-patent pharmaceutical products is questionable. For products that have gone off-patent and for those with similar chemical structure, a reference-pricing scheme and competition among generic alternatives results in effective price control, although incentives for generic substitution are weak (for patients) and misaligned (for pharmacists). When deciding whether a drug will be reimbursed through the social insurance scheme, the cost-effectiveness of new pharmaceuticals is not assessed. On the other hand, certain policy goals have been achieved. The accessibility and availability of medicines--including the most innovative products--is good; affordability is supported by relatively low average co-payment levels. While more expensive drugs usually have higher cost-sharing, drugs are not excluded from coverage on affordability grounds</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Slovak Republic</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Docteur, Elizabeth</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moïse, Pierre</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033315889</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UBA01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UEI01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UER01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UPA01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UBW01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FFW01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FNU01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">EUV01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FHR01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FHN01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">FHI01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/244264621247</subfield><subfield code="l">UBM01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047934395 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:02Z |
| indexdate | 2024-07-10T09:25:37Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033315889 |
| oclc_num | 1312706848 |
| open_access_boolean | |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (55 Seiten) 21 x 29.7cm |
| psigel | ZDB-13-SOC |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Kaló, Zoltán Verfasser aut Pharmaceutical Pricing and Reimbursement Policies in Slovakia Zoltán Kaló, Elizabeth Docteur and Pierre Moïse Paris OECD Publishing 2008 1 Online-Ressource (55 Seiten) 21 x 29.7cm txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers This paper examines aspects of the policy environment and market characteristics of Slovakia's pharmaceutical sector, and assesses the degree to which Slovakia has achieved certain policy goals. Pharmaceutical expenditure in Slovakia accounts for a higher share of total health expenditure than it does in any other OECD country, and the share of national income going to pharmaceuticals is exceeded only in Hungary. Although its relatively low national income is a partial explanation for Slovakia's status in this respect, this review finds that Slovakia has scope to reduce its expenditures and the rapid rate of growth in its pharmaceutical spending. Financing of pharmaceutical expenditure in Slovakia rests more heavily on the public sector than is typical in the OECD, with out-of-pocket spending accounting for just a quarter of total expenditure. The effectiveness of international price referencing in limiting Slovak prices for on-patent pharmaceutical products is questionable. For products that have gone off-patent and for those with similar chemical structure, a reference-pricing scheme and competition among generic alternatives results in effective price control, although incentives for generic substitution are weak (for patients) and misaligned (for pharmacists). When deciding whether a drug will be reimbursed through the social insurance scheme, the cost-effectiveness of new pharmaceuticals is not assessed. On the other hand, certain policy goals have been achieved. The accessibility and availability of medicines--including the most innovative products--is good; affordability is supported by relatively low average co-payment levels. While more expensive drugs usually have higher cost-sharing, drugs are not excluded from coverage on affordability grounds Social Issues/Migration/Health Slovak Republic Docteur, Elizabeth ctb Moïse, Pierre ctb https://doi.org/10.1787/244264621247 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Kaló, Zoltán Pharmaceutical Pricing and Reimbursement Policies in Slovakia Social Issues/Migration/Health Slovak Republic |
| title | Pharmaceutical Pricing and Reimbursement Policies in Slovakia |
| title_auth | Pharmaceutical Pricing and Reimbursement Policies in Slovakia |
| title_exact_search | Pharmaceutical Pricing and Reimbursement Policies in Slovakia |
| title_exact_search_txtP | Pharmaceutical Pricing and Reimbursement Policies in Slovakia |
| title_full | Pharmaceutical Pricing and Reimbursement Policies in Slovakia Zoltán Kaló, Elizabeth Docteur and Pierre Moïse |
| title_fullStr | Pharmaceutical Pricing and Reimbursement Policies in Slovakia Zoltán Kaló, Elizabeth Docteur and Pierre Moïse |
| title_full_unstemmed | Pharmaceutical Pricing and Reimbursement Policies in Slovakia Zoltán Kaló, Elizabeth Docteur and Pierre Moïse |
| title_short | Pharmaceutical Pricing and Reimbursement Policies in Slovakia |
| title_sort | pharmaceutical pricing and reimbursement policies in slovakia |
| topic | Social Issues/Migration/Health Slovak Republic |
| topic_facet | Social Issues/Migration/Health Slovak Republic |
| url | https://doi.org/10.1787/244264621247 |
| work_keys_str_mv | AT kalozoltan pharmaceuticalpricingandreimbursementpoliciesinslovakia AT docteurelizabeth pharmaceuticalpricingandreimbursementpoliciesinslovakia AT moisepierre pharmaceuticalpricingandreimbursementpoliciesinslovakia |